Eric Siemers Biography and Net Worth

Chief Medical Officer of Acumen Pharmaceuticals

Eric Siemers, MD, has more than 25 years experience overseeing clinical trials of neurodegenerative disease and joined Acumen as Chief Medical Officer in 2018. He joined Eli Lilly and Company in 1998 and was responsible for several clinical trials for Alzheimer’s compounds, including five phase III studies as well as phase I and II studies. Prior to Lilly, Dr. Siemers founded the Indiana University Movement Disorder Clinic, where his research included Parkinson’s and Huntington’s disease. Dr. Siemers served on the NIA/Alzheimer’s Association working group that proposed new research nomenclature for Alzheimer’s disease utilizing biomarkers and clinical symptoms. He was a founding member of the Alzheimer’s Association Research Roundtable and was on the steering committee for the Alzheimer’s Disease Neuroimaging Initiative. Dr. Siemers earned his MD from the Indiana University School of Medicine.

What is Eric Siemers' net worth?: The estimated net worth of Eric Siemers is at least $572.03 thousand as of January 22nd, 2026. Dr. Siemers owns 255,371 shares of Acumen Pharmaceuticals stock worth more than $572,031 as of August 5th. This net worth evaluation does not reflect any other investments that Dr. Siemers may own. Learn More about Eric Siemers' net worth.
How do I contact Eric Siemers?: The corporate mailing address for Dr. Siemers and other Acumen Pharmaceuticals executives is , , . Acumen Pharmaceuticals can also be reached via phone at 434-297-1000 and via email at [email protected]. Learn More on Eric Siemers' contact information.
Has Eric Siemers been buying or selling shares of Acumen Pharmaceuticals?: Eric Siemers has not been actively trading shares of Acumen Pharmaceuticals during the last ninety days. Most recently, Eric Siemers sold 895 shares of the business's stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $1.82, for a transaction totalling $1,628.90. Following the completion of the sale, the insider now directly owns 255,371 shares of the company's stock, valued at $464,775.22. Learn More on Eric Siemers' trading history.
Who are Acumen Pharmaceuticals' active insiders?: Acumen Pharmaceuticals' insider roster includes Marc Benioff (CEO), Nathan Fountain (Director), Paul Manning (Director), Daniel O'Connell (Chief Executive Officer), Derrell Porter (Director), Eric Siemers (Chief Medical Officer), and John Stalfort, III (Director). Learn More on Acumen Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Acumen Pharmaceuticals?: During the last year, insiders at the sold shares 30 times. They sold a total of 188,518 shares worth more than $374,717.53. The most recent insider tranaction occured on June, 17th when Director Derrell Porter sold 13,040 shares worth more than $30,383.20. Insiders at Acumen Pharmaceuticals own 10.2% of the company. Learn More about insider trades at Acumen Pharmaceuticals.
Information on this page was last updated on 6/17/2026.

Eric Siemers Insider Trading History at Acumen Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/22/2026	Sell	895	$1.82	$1,628.90	255,371
1/21/2026	Sell	2,331	$1.80	$4,195.80	256,266
1/6/2026	Sell	6,834	$1.97	$13,462.98	159,464
1/5/2026	Sell	4,000	$1.96	$7,840.00	166,298
1/21/2025	Sell	3,219	$1.59	$5,118.21	170,298
1/3/2025	Sell	10,859	$1.85	$20,089.15	106,717

Eric Siemers Buying and Selling Activity at Acumen Pharmaceuticals

Acumen Pharmaceuticals Company Overview

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Today's Range

Now: $2.27

$2.22

$2.29

50 Day Range

MA: $2.37

$2.11

$2.77

2 Week Range

Now: $2.27

$1.19

$3.60

Volume

23,482 shs

Average Volume

605,192 shs

Market Capitalization

$163.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36